DSCI Share Price

Open 6.95 Change Price %
High 7.00 1 Day 0.05 0.72
Low 6.95 1 Week 0.03 0.43
Close 7.00 1 Month 1.40 25.00
Volume 88916 1 Year 3.58 104.68
52 Week High 7.00
52 Week Low 2.85
DSCI Important Levels
Resistance 2 7.05
Resistance 1 7.03
Pivot 6.98
Support 1 6.97
Support 2 6.95
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Derma Sciences, Inc. (NASDAQ: DSCI)

DSCI Technical Analysis 5
As on 20th Jan 2017 DSCI Share Price closed @ 7.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.32 & Strong Buy for SHORT-TERM with Stoploss of 5.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
DSCI Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DSCI Other Details
Segment EQ
Market Capital 147873264.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website http://www.dermasciences.com
DSCI Address
DSCI
214 Carnegie Center
Suite 300
Princeton, NJ 08540
United States
Phone: 609-514-4744
Fax: 609-514-8554
DSCI Latest News
Derma Sciences pays $13m for Medihoney ahead of Integra buyout   Mass Device   - 18th Jan 17
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale ...   Business Wire (press release)   - 18th Jan 17
Harwood Feffer LLP Announces Investigation of Derma Sciences Inc.   PR Newswire (press release)   - 18th Jan 17
DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ...   PR Newswire (press release)   - 14th Jan 17
Latham & Watkins Steers Integra In $204M Derma Sciences Buy   Law360 (subscription)   - 12th Jan 17
Derma Sciences Buys MEDIHONEY® Brand From Long-Term Partner   Business Wire (press release)   - 12th Jan 17
Derma Sciences closes $80m deal for BioD   Mass Device   - 12th Aug 16
Derma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced ...   Business Wire (press release)   - 28th Jul 16
Derma Sciences Announces Leadership and CEO Transition   Business Wire (press release)   - 21st Dec 15
Derma Sciences Announces Results of Futility Analyses for Phase 3 Clinical ...   Business Wire (press release)   - 12th Nov 15
Interactive Technical Analysis Chart Derma Sciences, Inc. ( DSCI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Derma Sciences, Inc.
DSCI Business Profile
Derma Sciences, Inc. (Derma Sciences), is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. pharmaceutical wound care, advanced specialty medical device/pharmaceutical company with a primary focus on wound care. The Company has one pharmaceutical wound care product candidate that has completed a Phase 2 study and is working towards initiation of a Phase 3 study in 2012. The majority of its products are sold through distributors to various health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians� offices. Some of its products are sold through retail channels. Effective September 4, 2013, Derma Sciences Inc acquired a 7.3% stake in Comvita Ltd, a manufacturer and wholesaler of natural health products.